InMode reported Q2 2026 revenue of $95.6 million, beating FactSet consensus of $93.1 million and demonstrating sustained demand for its radiofrequency and ultrasonic microneedling platforms in the U.S. market. The beat came despite a competitive device landscape and ongoing capital-equipment purchasing cycles that typically lag consumer demand.
Devices & Tech
InMode Q2 Revenue Beats Estimates at $95.6M
Device manufacturer tops analyst expectations, signaling steady U.S. aesthetic-device demand.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Revenue of $95.6M beat FactSet consensus of $93.1M.
For practice owners, InMode's outperformance signals that device utilization and patient volume remain solid, particularly for RF microneedling and ultrasonic modalities. However, the modest beat ($2.5M above consensus) suggests the market is pricing in slower growth ahead. Owners should evaluate their own device ROI and patient-per-week metrics against industry trends; if your utilization lags, competitive pressure on device pricing and financing terms will likely intensify as manufacturers compete for floor space.
Source: original report ↗
Frequently asked questions
What was InMode's Q2 2026 revenue and did it beat expectations?
InMode reported Q2 2026 revenue of $95.6 million, beating FactSet consensus estimates of $93.1 million by $2.5 million. This beat demonstrates sustained demand for its radiofrequency and ultrasonic microneedling platforms in the U.S. aesthetic market.
What does InMode's earnings beat mean for med spa owners?
The beat signals that device utilization and patient volume remain solid for RF microneedling and ultrasonic modalities. However, the modest $2.5M beat suggests slower growth ahead, meaning med spa owners should evaluate their own device ROI and patient-per-week metrics to stay competitive.
Why is InMode's Q2 beat modest despite beating estimates?
The $2.5 million beat is considered modest because the market is pricing in slower growth ahead, reflecting a competitive device landscape and capital-equipment purchasing cycles that typically lag consumer demand. This suggests manufacturers will face pricing pressure and need to compete harder for floor space.
How should med spa owners use InMode's earnings to benchmark their practice?
Owners should compare their device utilization rates and patient-per-week metrics against industry trends revealed by InMode's performance. If your utilization lags industry standards, expect competitive pressure on device pricing and financing terms as manufacturers compete for practice partnerships.
What aesthetic devices is InMode seeing strong demand for?
InMode is seeing strong demand for its radiofrequency (RF) microneedling and ultrasonic microneedling platforms in the U.S. market. These modalities remain core drivers of the company's revenue growth despite a competitive device landscape.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.